Ruminations on the future of pharmacovigilance – new podcast out now

Perspective / 15 December 2022

After the pandemic: what were the lessons learnt for pharmacovigilance? Find out in the latest episode of the Drug Safety Matters podcast.

COVID-19 forced pharmacovigilance experts to revisit their processes to deal with unprecedented volumes of data and catch unexpected safety issues.

Elena Rocca of Oslo Metropolitan University joins Drug Safety Matters host Federica Santoro in the studio for a philosophical inquiry into the lessons to be learnt from the pandemic – and what it can teach us about the science of drug safety.

Subscribe by visiting the Drug Safety Matters website or listen in right here:

You may also like

Opinion: Hard lessons prime PV experts and regulators for present challenges

In this opinion article, Maria Mantziri and Natália Hromníková argue how contrasting examples from pharmacovigilance’s past could point to a more proactive and vital future.

Perspective / 29 June 2021

Stamping out drug adversity

The identification of medicinal products (IDMP) standards will help make sure patients get the right medicines and make it easier to detect problems when things go wrong.

Perspective / 29 August 2022

Diagnosing and prescribing through the pharmacovigilance lens

Pharmacovigilance produces valuable safety data, but is it used to its full value, and how can primary healthcare workers make more use of PV findings in diagnosis and prescribing?

Perspective / 20 April 2022

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more